In patients with ankylosing spondylitis, infliximab does not inhibit structural damage, although it may have other beneficial effects, according to European and US researchers. Reuters Health Information
This new review explores a wide array of new therapeutic options for the treatment of systemic sclerosis, including biologic and immunosuppressive therapies, among others. Nature Reviews Rheumatology
Join a discussion with Drs. Clauw, Goldenberg, and Sandhu, and get the latest updates from ACR 2007 on important issues about fibromyalgia -- diagnosis, management, and controversies. Medscape Rheumatology
